Caplight Directory>Companies>Pan Cancer T-preview>Pancancer-t


Pan Cancer T

Pan Cancer T

Private
RotterdamHealthcare & Life Scienceshttps://pancancer-t.com

Last Round

Early Funding

Dec 8, 2025

Total Funding Raised

$16.28M

Company Overview

Pan Cancer T is a biotechnology company that develops T cell receptor (TCR) T cell therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

TCR-T cell therapysolid tumor therapycell therapycancer immunotherapyengineered T-cellsTCR discoveryautologous cell therapyTCR:CO-STIM platformantigen discoverytriple-negative breast cancerTNBCmelanoma therapyT-cell fitnesstumor microenvironmentbiotech licensingpreclinical biotechovarian cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pan Cancer T Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pan Cancer T Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingDec 8, 2025
SeedJul 11, 2024
SeedOct 28, 2021
SeedFeb 8, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Rachel Abbott

Chief Executive Officer

Executive Team

Pan Cancer T Investors

Notable investors and investment history

InvestorRounds
Swanbridge CapitalSeed
Thuja CapitalSeed, Early Funding
Van Herk VenturesSeed, Early Funding
InnovationQuarterEarly Funding, Seed
View all Investors

Pan Cancer T Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pan Cancer T Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pan Cancer T's valuation, stock price, and market status.

Firmographic Details

HeadquartersRotterdam
Employee Range15
Year Founded2020
Last FundingDec 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.